Some four years into its run as an independent women’s health outfit, Organon is parting ways with its first CEO after an ...

On Friday, the FDA approved Bayer’s dual neurokinin (NK) targeted therapy elinzanetant, which will now be marketed in the U.S ...

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...

Ipsen unveiled a new educational initiative dedicated to supporting teenagers and young adults in the transition from their ...

As a newly christened manufacturing facility comes online in one part of Ireland, Merck KGaA plans to turn out the lights at ...

After popular pain med Tylenol came under fire from officials in the Trump administration for an alleged link to autism if ...

Dermatology specialist Galderma has hopped on the U.S. manufacturing bandwagon, revealing a commitment to spend more than ...

Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies.

With another quarter of growth in the books, Swiss CDMO Lonza is continuing to regain its forward momentum as it seeks to ...

For the first nine months of 2025, Roche’s overall sales grew 7% at constant currencies to 45.9 billion Swiss francs (nearly ...

After clearing Novo Nordisk’s semaglutide treatments Ozempic and Wegovy to reduce the risk of major adverse cardiovascular ...